The stock of Aclaris Therapeutics Inc (NASDAQ:ACRS) is a huge mover today! About 1.30 million shares traded hands or 962.84% up from the average. Aclaris Therapeutics Inc (NASDAQ:ACRS) has risen 16.57% since April 14, 2016 and is uptrending. It has outperformed by 11.88% the S&P500.
The move comes after 6 months negative chart setup for the $473.41M company. It was reported on Nov, 16 by Barchart.com. We have $18.68 PT which if reached, will make NASDAQ:ACRS worth $56.81 million less.
Aclaris Therapeutics Inc (NASDAQ:ACRS) Ratings Coverage
Out of 4 analysts covering Aclaris Therapeutics (NASDAQ:ACRS), 3 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 75% are positive. Aclaris Therapeutics has been the topic of 8 analyst reports since November 2, 2015 according to StockzIntelligence Inc. JMP Securities initiated the shares of ACRS in a report on Friday, September 30 with “Market Perform” rating. The firm earned “Buy” rating on Friday, June 10 by Guggenheim. Jefferies initiated Aclaris Therapeutics Inc (NASDAQ:ACRS) rating on Monday, November 2. Jefferies has “Buy” rating and $20 price target. The firm has “Buy” rating given on Monday, November 2 by Citigroup. The firm earned “Buy” rating on Friday, August 12 by Jefferies. On Monday, September 19 the stock rating was maintained by Jefferies with “Buy”. The rating was initiated by William Blair on Monday, November 2 with “Outperform”.
According to Zacks Investment Research, “Aclaris Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing drugs to met needs in dermatology. Its drug candidate consists of A-101, a high-concentration hydrogen peroxide topical solution which is being developed as a prescription treatment for seborrheic keratosis a common non-malignant skin tumor and A-102, a proprietary topical gel dosage form of hydrogen peroxide for the treatment of SK and common warts which are in different clinical trial. Aclaris Therapeutics, Inc. is headquartered in Malvern, Pennsylvania.”
More important recent Aclaris Therapeutics Inc (NASDAQ:ACRS) news were published by: Investorplace.com which released: “3 Stocks to Watch on Wednesday: Aclaris Therapeutics Inc (ACRS), Agilent …” on November 16, 2016, also Businesswire.com published article titled: “Aclaris Therapeutics International and Rigel Sign License Agreement for JAK …”, Quotes.Wsj.com published: “News Aclaris Therapeutics Inc.ACRS” on February 20, 2011. More interesting news about Aclaris Therapeutics Inc (NASDAQ:ACRS) was released by: Globenewswire.com and their article: “Aclaris Therapeutics, Inc. Appoints Brett Fair as Senior Vice President of …” with publication date: December 16, 2015.
ACRS Company Profile
Aclaris Therapeutics, Inc., incorporated on July 13, 2012, is a clinical-stage specialty pharmaceutical company. The Firm is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.